From JCR to ACR: Recent Perspectives on IgG4-Related Diseases & IL-6-Targeting Treatment

Moderator(s)

• 

  Tsutomu Takeuchi, MD, PhD

  Div. Rheumatology, Keio University
• 

  Yoshiya Tanaka, MD, PhD

  University of Occupational and Environmental Health, Japan

Speaker(s)

• 

  Hisanori Umehara, MD

  Department of Rheumatology and Immunology, Nagahama City Hospital,
• 

  Mitsuhiro Kawano, MD, PhD

  Kanazawa University
• 

  Hajime Yoshifuji, MD, PhD

  Kyoto University
• 

  Yuko Kaneko, MD, PhD

  Keio University

The concept of IgG4-related diseases originated in Japan about 15 years ago. The concept, diagnostic criteria and treatment of the IgG4-related diseases have been emerging. At this session, two faculty experts will present seminars on updates in IgG4-related disease. Talks will explore IL-6, which was first reported in Japan in 1986, and the anti-IL-6 receptor antibody tocilizumab, which was initially approved for the treatment of rheumatoid arthritis in Japan. Tocilizumab's application has been expanded to other refractory diseases, including large-vessel arteritis and adult-onset Still's disease. This session will review differential diagnosis of IGg4-related diseases, optimal therapeutic strategies, and the efficacy and safety of IL-6 inhibition therapy in this patient population, as well as those with large-vessel vasculitis and adult-onset Still's disease.

Learning Objectives:

• Describe the pathophysiology of IgG4-related diseases and abnormal immunity in these patients
• Review the differential diagnosis of IgG4-RD, MCD and ANCA-associated vasculitis and optimal therapeutic strategies to prevent recurrence and permanent organ injury
• Review the etiology of large-vessel vasculitis and assess the efficacy and safety of IL-6 inhibition therapy in patients with large-vessel vasculitis
• Describe adult-onset Still's disease, its pathogenesis, and the efficacy and safety of IL-6 inhibition in the management of adult-onset Still's disease

Presentations:

• 4:00 PM – 4:10 PM ET

  Front Line of the Pathogenesis and Autoantigens of IgG4-Related Disease
  Hisanori Umehara, MD – Department of Rheumatology and Immunology, Nagahama City Hospital,
• 4:10 PM – 4:15 PM ET

  Q&A
• 4:15 PM – 4:25 PM ET

  Recent Topics in Diagnosis and Treatment of IgG4-Related Disease
  Mitsuhiro Kawano, MD, PhD – Kanazawa University
• 4:25 PM – 4:30 PM ET

  Q&A
• 4:30 PM – 4:40 PM ET

  Genetic Backgrounds and Pathology of Large Vessel Vasculitis: Utility of IL-6 Inhibition Therapy
  Hajime Yoshifuji, MD, PhD – Kyoto University
• 4:40 PM – 4:45 PM ET

  Q&A
• 4:45 PM – 4:55 PM ET

  IL-6 Inhibition in Adult-Onset Still’s Disease
  Yuko Kaneko, MD, PhD – Keio University
• 4:55 PM – 5:00 PM ET

  Q&A